Big Board Alerts

September 14, 2023
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology

AbCellera announced that it has entered into a strategic collaboration with Incyte to discover and develop therapeutic antibodies in oncology.

“We are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need,” said Murray McCutcheon, Ph.D., Senior Vice President of Partnering at AbCellera. “We look forward to working as an extension of Incyte’s team to address complex antibody discovery challenges and accelerate the development of Incyte’s preclinical pipeline of oncology medicines.”

“This collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment options for patients with cancer,” said Patrick Mayes, Ph.D., Vice President, BioTherapeutics at Incyte. “We are excited to partner with AbCellera to initiate this research and look forward to collaborating with them to identify new antibody therapeutics that may address unmet needs in oncology.”

Under the financial terms of the agreement, Incyte has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and regulatory milestone payments and royalties on net sales of products.

The post AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology appeared first on Pharma Journalist.

 

Latest Articles

DON’T MISS THE OPPORTUNITY TO JOIN OUR MARKET SUMMARY REPORT FOR A LIMITED TIME

By submitting this form on our website, you agree that we may collect and use your personal information for marketing, and for other purposes as set forth in our privacy policy, which we encourage you to review.